###### Strengths and limitations of this study

-   We included a large sample of participants with acute whiplash-associated disorders.

-   We used block randomisation to allocate participants to the treatment groups.

-   We concealed treatment allocation.

-   We used a patient-centred outcome (self-reported recovery) as the primary outcome, which was measured by a study interviewer who was blind to the treatment allocation.

-   The main threats to the validity of the trial are loss to follow-up and the inability to blind participants to the received treatment.

Introduction {#s1}
============

Whiplash-associated disorder (WAD) is the most common traffic injury.[@R1] WAD leads to a significant burden of disability and healthcare utilisation, and increases the risk of future health problems such as neck pain, headaches, low back pain, shoulder pain and sleep disturbances.[@R1] Poor prognostic factors for WAD include history of neck pain related to a traffic collision, older age, high initial pain levels and psychological factors (eg, poor expectation of recovery, depressive symptoms).[@R11]

The clinical management of acute WAD is complex, and focuses on conservative interventions to manage symptoms and improve recovery.[@R13] Evidence suggests that the type, intensity and timing of healthcare delivery may impact recovery, but the evidence is mixed.[@R6] A randomised trial reported that multidisciplinary individualised treatments led to similar outcomes to usual care (from general practitioners, physiotherapists or chiropractors) in patients with acute WAD.[@R21] Patients receiving high-intensity healthcare from general practitioners, physiotherapists or chiropractors within the first month of injury experience slower recovery than patients who visited general practitioners once or twice.[@R6] Similarly, patients attending an early intensive multidisciplinary rehabilitation programme report slower recovery than those who received usual insured individual care.[@R17] However, a randomised trial reported that a physiotherapy package (up to six sessions) provided slightly faster recovery than one additional physiotherapy advice session when added to emergency department consultations.[@R20] Overall, the body of evidence suggests that too much treatment too early after WAD may delay recovery,[@R22] but further research is needed.

In 2008, the Bone and Joint Task Force on Neck Pain and its Associated Disorders (Neck Pain Task Force) recommended that the medical management of acute WAD without radiculopathy should include education, reassurance, pain management and rapid discharge.[@R24] Moreover, the Neck Pain Task Force recommended that rehabilitation providers use exercise, manual therapy and education to effectively manage acute WAD without radiculopathy.[@R25] Recently, exorbitant healthcare costs and increasing disability rates have led governments (through regulations and legislations) and insurers (through preferred-provider networks) to implement guidelines for the treatment of WAD.[@R1] Most guidelines emphasise education, reassurance, mobility, return-to-activity and exercise,[@R29] but little evidence supports their effectiveness.[@R32] In Ontario, the provincial government introduced guidelines (in the form of regulations) to ensure timely access to rehabilitation services, improve the utilisation of healthcare resources and establish consistent fee schedules for insurers and healthcare providers.[@R29]

Our primary objective was to evaluate the effectiveness of a government-regulated rehabilitation guideline compared with education and activation (promoting self-care and early return to normal activities of daily living) by general practitioners, and to a preferred-provider insurance-based rehabilitation programme on self-reported global recovery from acute WAD grades I--II. Our secondary objectives aimed to determine which of the three interventions was more effective in reducing time on insurance benefits, neck pain intensity, whiplash-related disability, depressive symptoms and in improving health-related quality of life.

Methods {#s2}
=======

Design and source population {#s2a}
----------------------------

We conducted a pragmatic randomised controlled trial ([figures 1 and 2](#F1 F2){ref-type="fig"}).[@R33] We registered the trial at [www.clinicaltrials.gov](www.clinicaltrials.gov) (NCT00546806). Participants were eligible for the study if they: 1) were ≥18 years; 2) resided or worked within the Greater Toronto Area, Mississauga, Burlington, Cambridge, Kitchener, Ajax or Pickering and 3) were injured in a traffic collision and made an insurance claim to AVIVA Canada between February 2008 and March 2011. AVIVA Canada is a national casualty and property insurer that held 9.5% of the automobile insurance market in Ontario at the time of the study.[@R34]

![Consolidated Standards of Reporting Trials diagram.](bmjopen-2017-021283f01){#F1}

![Consolidated Standards of Reporting Trials diagram (continued).](bmjopen-2017-021283f02){#F2}

Inclusion and exclusion criteria {#s2b}
--------------------------------

Insurance adjusters (who manage insurance claims) informed claimants about the trial when making a claim. Claimants interested in the study were referred to a trial coordinator who confirmed eligibility and arranged for a clinical assessment. The trial coordinator assessed inclusion and exclusion criteria using a standardised history, physical examination and diagnostic imaging if clinically indicated.

Individuals who met the following criteria were included: 1) insurance claim for physical injury and interviewed within 21 days of the traffic collision; 2) diagnosed with grade I--II WAD; 3) average neck pain since the collision ≥3/10 on the Numerical Rating Scale and 4) completed interviews in English. Excluded were individuals with: 1) fracture/dislocation of the spine or major bone; 2) head trauma with loss of consciousness; 3) past whiplash or work-related neck injury within the year; 4) active systemic diseases (cancer, inflammatory arthritis, disorders of central nervous system); 5) previous neck surgery and 6) treated by physiotherapist or chiropractor for neck pain in the 3 months before the injury. All participants provided written informed consent.

Randomisation to treatment groups {#s2c}
---------------------------------

Participants were randomly allocated to: 1) the government-regulated guideline; 2) education and activation by a general practitioner or 3) the preferred-provider insurance-based rehabilitation programme. Participants from the same motor vehicle were allocated to the same treatment arm to minimise contamination and cross-over. A co-principal investigator independently performed central randomisation using NQuery Advisor 7.09.[@R35] We used block randomisation with random block sizes of 3, 6, 9 and 12 participants for each study site; treatment allocation was concealed by providing trial coordinators with sequentially numbered sealed opaque envelopes for each study site.

Interventions {#s2d}
-------------

Participants received their interventions in person and individually within multidisciplinary rehabilitation (physiotherapists, kinesiologists, occupational therapists and massage therapists) or general practitioner clinics in Toronto, Mississauga, Cambridge, Ajax and Pickering, Ontario. All clinicians received training about the treatment protocols. Clinicians provided care to one treatment arm only. As recommended by the Ontario Government regulatory body, all participants received an educational brochure entitled 'Getting the Facts about Whiplash\'.[@R36]

Government-regulated guideline {#s2e}
------------------------------

The goal of the government-regulated guideline was to ensure timely access to rehabilitation services, improve healthcare utilisation and establish consistent fee schedules for insurers and healthcare providers.[@R29] The treatment was multimodal, tailored to participants' needs and could include: 1) education, reassurance, home stretching exercises and encouragement to resume normal activities; 2) clinic-based exercises and functional activities; 3) manipulation or mobilisation; 4) pain management modalities (including massage therapy) and 5) coping skills education (online [supplementary appendix 1](#SP1){ref-type="supplementary-material"}).[@R36] The physiotherapists determined the duration, frequency and number of visits, which was limited to 10 during the first 3 weeks of care, and to 9 after 3 weeks, for the period extending from weeks 4 to 6.
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Participants with functional limitations were eligible for an assessment by an occupational therapist, which could lead to: 1) recommendation to use aids or devices; 2) minor modifications in the work, home or school environment; 3) instructions on adaptive strategies or alternative approaches to fulfil functional tasks and 4) specific functional activities.

Participants who reported significant improvement in the first 6 weeks of care, but had not reached satisfactory clinical recovery, were eligible to receive up to four additional treatment sessions over a 2-week period. The physiotherapist re-evaluated participants who had not recovered by 9 weeks and developed a new plan of management that was submitted to the insurer.

Preferred-provider insurance-based rehabilitation programme {#s2f}
-----------------------------------------------------------

The rehabilitation programme was designed by AVIVA Canada to initiate care within a preferred-provider network in a timely and efficient manner by removing administrative barriers (claim paper work) associated with the claim initiation process. The insurer hypothesised that providing quick access to care and reducing the administrative burden on claimants would prevent adversarial relationships and facilitate recovery.

The clinical interventions included in the preferred-provider insurance-based rehabilitation programme were similar to the government-regulated guideline (online [supplementary appendix 1](#SP1){ref-type="supplementary-material"}). A maximum of nine treatments (including massage therapy) were allowed during first 3 weeks postcollision with an additional eight sessions (including massage therapy) during the subsequent 3 weeks if necessary. The physiotherapist determined the duration, interventions and frequency of visits, and recommended an in-home or job-site functional assessment if indicated. The primary differences between the government-regulated guideline and the preferred-provider insurance-based rehabilitation programme were: 1) a reduction of the administrative burden for the claimant and 2) the possibility of participants who did not recover during the first 6 weeks of care to be referred (at the discretion of the physiotherapist) for a multidisciplinary evaluation at one of the study clinics.

Education and activation by general practitioner {#s2g}
------------------------------------------------

The education and activation intervention programme promoted self-care and early return to normal activities (online [supplementary appendix 1](#SP1){ref-type="supplementary-material"}). Study general practitioners were asked to see participants once unless follow-up was clinically indicated. During the initial consultation, the general practitioner: 1) reassured the participant about the favourable prognosis of WAD; 2) encouraged the participant to resume normal activities; 3) recommended home stretching exercises for the area of complaint (neck, shoulder, back and hip) and 4) if indicated, prescribed pain relief modalities or medication (heat/ice, acetaminophen or non-steroidal anti-inflammatory drug). Participants were informed to contact the general practitioner should their complaint persist or worsen. If follow-up visits were necessary, the general practitioner re-assessed the participant and the education and activation intervention was repeated. The maximum number of visits during the first 6 weeks was two for this treatment arm. Participants who did not recover during the first 6 weeks of care could be referred (at the discretion of the general practitioner) for a multidisciplinary evaluation at one of the study clinics.

Multidisciplinary evaluation {#s2h}
----------------------------

The multidisciplinary evaluation (by a physiotherapist and kinesiologist) involved a functional evaluation and recommendation for further physiotherapy care or an interdisciplinary rehabilitation programme to overcome psychosocial barriers to return to function, and facilitate physical and functional restoration if deemed appropriate. This programme included up to 5 weeks of daily intervention. The interdisciplinary team (involving a physiotherapist, general practitioner, occupational therapist, psychologist and kinesiologist) determined the frequency, duration and type of care, which could include: 1) education and reassurance; 2) goal setting and advice on self-management; 3) psychological counselling and stress management; 4) relaxation therapy, psychotherapy and family counselling; 5) cognitive behavioural therapy; 6) instruction on pain management techniques and 7) strength, endurance, flexibility or cardiovascular exercises.

Data collection and follow-up {#s2i}
-----------------------------

Using a standardised questionnaire, a trial coordinator collected baseline data prior to randomisation (online [supplementary appendix 2](#SP1){ref-type="supplementary-material"}). Participants were followed at 6 weeks, and 3, 6, 9 and 12 months postinjury. Research assistants blind to treatment allocation collected all follow-up data primarily via telephone, or in-person at the treating clinic, if requested. During the first year of the trial, participant feedback and the lower participation than expected suggested that answering the questionnaire was too burdensome. Therefore, we offered participants who did not wish to complete the full follow-up questionnaire to answer either: 1) two outcome questions (self-reported global recovery and neck pain intensity) and a question used for the cost-effectiveness analysis (rating general health state on a Numerical Rating Scale) (data not reported in this paper) or 2) an abbreviated version of the full follow-up questionnaire (online [supplementary appendix 3](#SP1){ref-type="supplementary-material"}).

Outcomes {#s3}
========

Primary outcome {#s3a}
---------------

*Time to self-reported global recovery:* self-reported global recovery was measured with the self-reported global recovery question, which is valid and reliable in patients with WAD.[@R17] This ordinal transition scale has previously been used in randomised trials and cohort studies of neck pain.[@R17] In patients with WAD, we have previously reported that perceived recovery is consistently associated with less neck pain, better physical functioning and fewer depressive symptoms.[@R17] Participants were asked: \"How well do you feel you are recovering from your injuries?" and had the following choices: completely better; much improved; slightly improved; no change; slightly worse; much worse and worse than ever. Time to self-reported global recovery was measured as the number of days between the date of injury and the first follow-up date at which a participant reported being 'completely recovered' or 'much improved'.

Secondary outcomes {#s3b}
------------------

*Neck pain intensity in the past 24 hours:* the 11-point Numerical Rating Scale is a global measure of pain intensity anchored by two extremes of pain intensity ranging from 0 ('no pain') to 10 ('pain as bad as it could be'). It has good short-term test-retest reliability, good construct validity and can distinguish levels of pain in subjects with chronic pain.[@R42]

*Whiplash disability:* the Whiplash Disability Questionnaire consists of 13 items that measure the effect of whiplash on pain, personal care, work/home/study duties, driving/public transportation, sleep, tiredness/fatigue, social activity, sporting activity, non-sporting leisure activity, depression/sadness, anxiety, anger and concentration. Each item is scored from 0 to 10, with a total sum of 130, with higher global scores indicating more disability.[@R26] It has adequate reliability, validity and responsiveness.[@R26]

*Health-related quality of life:* the 36-item Short Form Survey (SF-36) includes eight individual scales (physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health) used to compute the physical component and mental component scores in the past 4 weeks. It is valid, reliable and responsive in participants with musculoskeletal conditions.[@R48]

*Depressive symptomatology:* the Centre for Epidemiological Studies-Depression Scale (CES-D) is a widely used 20-item self-report scale designed to measure current level of depressive symptomatology.[@R52] The CES-D is scored from 0 to 60 with higher scores indicating greater depressive symptomatology.[@R54] It has good test-retest reliability, and good factorial and discriminant validity.[@R54]

*Time on insurance benefit:* we measured number of days between date of injury and date of insurance claim closure. Claim closure corresponds to the end of treatment, attainment of maximal medical improvement, termination of income replacement benefits or date of payment of the last outstanding bill incurred by the claimant (eg, device purchased). AVIVA Canada provided the claim closure dates. Time to claim closure is a valid marker of time to health recovery (ie, lower levels of neck pain, better physical functioning and no depression).[@R60]

The secondary outcomes of 1) satisfaction with care and satisfaction with treatment and 2) recurrence described in our protocol are not reported in this manuscript. The full follow-up questionnaire was deemed too burdensome to participants and these outcomes were subsequently eliminated.

Co-interventions {#s3c}
----------------

We measured co-interventions by asking participants to self-report the type of healthcare provider consulted beyond those involved in delivering trial interventions (ie, chiropractor, physiotherapist, massage therapist, medical specialist, psychologist or counsellor and other healthcare providers (acupuncturist, naturopath, homeopath, Chinese medicine practitioner)).

Adverse events {#s3d}
--------------

We measured adverse events at each follow-up interview, defined as an unintended sign or symptom of the intervention (eg, neck pain, radiating pain in arms, feeling tired, headache, depression or other physical discomfort).

Sample size {#s3e}
-----------

We aimed to detect a 20% difference in rate of self-reported global recovery at 1 year using a log rank test with 80% power and a two-tail significance level of 0.05.[@R62] In our trial protocol, we specified 90% power.[@R33] We revised the power of the trial from 90% to 80% because of the challenges associated with recruitment. Using these parameters, we needed 86 participants per group. Assuming a 30% loss to follow-up per arm, we needed 336 participants (ie, 112 per arm).

Statistical analysis {#s3f}
--------------------

We conducted analyses according to the intention-to-treat principle. We described participant demographic and clinical characteristics at baseline (eg, mean, 95% CI, median, range) and conducted inference testing as appropriate (eg, t-test, Χ^2^ test, Kruskal-Wallis test).

Primary outcome {#s3g}
---------------

We used Kaplan-Meier estimates to derive median time to self-reported global recovery and 95% CI. Using the government-regulated group as the reference intervention, we quantified the relative effectiveness of interventions by computing the hazard rate ratio (HRR) and 95% CI using Cox proportional hazards models.[@R63] We computed the Wald Χ^2^ statistic to determine whether the difference between groups was significant (p\<0.05). We used two methods to test the proportionality assumption of our model. First, we tested the significance of an interaction term between the intervention groups and log of time. Second, we fitted piecewise proportional hazards models.

Baseline characteristics that differed between groups and changed either of the regression coefficients by 10% or more were controlled for in the primary analysis.[@R68] Observations were censored at 3 weeks for participants who dropped out prior to the first follow-up interview, or on the date of their last completed follow-up interview for those who provided follow-up data.

Secondary outcomes {#s3h}
------------------

We computed mean differences (and 95% CI) within and between groups from baseline to each follow-up point. We used standardised cut-off values to determine if clinically important differences were reached at each time point: 1) two points on the 11-point Numeric Rating Scale[@R37]; 2) 21.4 points on the Whiplash Disability Questionnaire (ie, the minimal detectable change)[@R46] and 3) 7.7 points for the SF-36 Physical Component Score.[@R69] The minimal clinically important differences for CES-D and SF-36 Mental Component Score have not been established in this population; therefore, we considered a 10% change from baseline to be clinically important. We used Generalised Estimating Equations models to account for effects due to study arm, different follow-up times and the interaction between study arm and follow-up times. We used an exchangeable correlation structure to account for within-subject correlation over time. Finally, we used Kaplan-Meier estimates to derive median time to claim closure and Cox proportional hazards models to analyse time on insurance benefits according to the methods described above.[@R63]

Patient and public involvement {#s3i}
------------------------------

Patients were not involved in the development of the research question, study design, choice of outcome measures or recruitment for the study. Participants did not assess the burden of the interventions. We will use social media and our university website to inform the public about the results of the study.

Results {#s4}
=======

Study sample {#s4a}
------------

We received 1348 referrals and 422 individuals from 336 automobile collisions were clinically assessed for inclusion in the trial. Of these, 340 participants were randomised: 113 cars (115 participants) to the government-regulated guideline, 113 cars (113 participants) to the preferred-provider group and 110 cars (112 participants) to education and activation ([figures 1 and 2](#F1 F2){ref-type="fig"}; online [supplementary appendix 4](#SP1){ref-type="supplementary-material"}). Overall, 86.7% of participants received the allocated intervention (at least one session): 83.5% for the government-regulated guideline, 84.1% for preferred-provider rehabilitation and 92.9% for the education and activation group.

Sample characteristics {#s4b}
----------------------

Baseline characteristics were well balanced between groups ([table 1](#T1){ref-type="table"}). The mean physical component score of the SF-36 and active coping score were higher in the government-regulated guideline group, but these differences were small and therefore not clinically meaningful. The education and activation group included a smaller proportion of employed participants and a larger proportion of participants with hypertension. Finally, the preferred-provider group included a smaller proportion of participants who expected to get better soon. Among these baseline characteristics, only expectation of recovery changed the regression coefficients by at least 10% (online [supplementary appendix 5](#SP1){ref-type="supplementary-material"}). Therefore, expectation of recovery was adjusted for in the primary analysis.

###### 

Baseline characteristics

  Variable                                                     Government-regulated guideline n=115   Preferred-provider insurance-based rehabilitation n=113   General practitioner education and activation n=112
  ------------------------------------------------------------ -------------------------------------- --------------------------------------------------------- -----------------------------------------------------
  Sociodemographic                                                                                                                                              
   Female, N (%)                                               81 (70.4)                              70 (61.9)                                                 78 (69.6)
   Age, mean (SD)                                              38.9 (11.7)                            39.5 (12.1)                                               43.2 (15.2)
   Marital status: N (%)                                                                                                                                        
     Married/common law                                        60 (52.2)                              62 (54.9)                                                 62 (55.4)
     Single/never married                                      33 (28.7)                              35 (31.0)                                                 30 (26.8)
    Separated/divorced/widowed                                 22 (19.1)                              16 (14.2)                                                 20 (17.9)
   Educational level: N (%)                                                                                                                                     
     High school or less                                       23 (20.0)                              21 (18.6)                                                 26 (23.2)
     Some postsecondary/technical school                       52 (45.2)                              57 (50.4)                                                 46 (41.1)
     University graduate                                       40 (34.8)                              35 (31.0)                                                 40 (35.7)
   Income level: N (%)                                                                                                                                          
     ≤US\$49 000                                               57 (50.0)                              53 (46.8)                                                 58 (51.9)
     US\$50 000--US\$79 999                                    39 (33.9)                              32 (27.9)                                                 31 (27.8)
     ≥US\$80 000                                               19 (16.1)                              28 (25.2)                                                 23 (20.4)
   Employed at the time of the collision, N (%)                98 (85.2)                              101 (89.4)                                                87 (77.7)
    Dependents, N (%), n=338                                                                                                                                    
     None                                                      51 (44.4)                              51 (45.1)                                                 62 (56.4)
     2--3                                                      46 (40.0)                              48 (42.5)                                                 32 (29.1)
     ≥3                                                        18 (15.7)                              14 (12.4)                                                 16 (14.6)
   Legal/insurance variables at the baseline interview                                                                                                          
   Arguing with insurer, N (%)                                 6 (5.3)                                9 (8.0)                                                   6 (5.4)
   Lawyer involvement, N (%)                                   4 (3.5)                                8 (7.1)                                                   8 (7.1)
  Collision                                                                                                                                                     
   Days since collision, median (IQR)                          6.0 (5.0)                              5.0 (5.0)                                                 6.0 (6.0)
   Car stopped, N (%)                                          56 (49.1)                              49 (42.5)                                                 49 (43.6)
   Position in car, N (%), n=339\*                                                                                                                              
     Driver                                                    103 (90.4)                             106 (93.8)                                                99 (88.4)
     Front seat passenger                                      7 (6.1)                                5 (4.4)                                                   9 (8.0)
     Back seat passenger                                       3 (2.6)                                1 (0.9)                                                   3 (2.7)
     Cyclist                                                   1 (0.9)                                1 (0.9)                                                   1 (0.9)
   Direction of impact, N (%)                                                                                                                                   
     Front                                                     18 (15.8)                              31 (27.4)                                                 26 (23.2)
     Rear                                                      56 (49.1)                              51 (45.1)                                                 53 (47.3)
     Driver side                                               11 (9.6)                               16 (14.2)                                                 12 (10.7)
     Passenger side                                            16 (14.0)                              6 (5.3)                                                   16 (14.3)
     Other                                                     13 (11.4)                              9 (8.0)                                                   5 (4.5)
   Car drivable postcollision, N (%)                           54 (47.3)                              47 (41.3)                                                 51 (45.9)
   Seat belt fastened, N (%), n=334\*                          111 (99.1)                             110 (99.1)                                                109 (98.2)
   Head rest, N (%), n=330\*                                   110 (99.1)                             111 (99.1)                                                104 (95.4)
   Number of occupants in vehicle, N (%), n=337                                                                                                                 
    1                                                          73 (64.0)                              86 (76.8)                                                 83 (74.8)
    2--3                                                       37 (32.5)                              21 (18.8)                                                 26 (23.4)
    ≥4                                                         4 (3.5)                                5 (4.5)                                                   2 (1.8)
   Previous injury claim in past 2 years, N (%), n=340         0                                      0                                                         2 (1.8)
   Number of personal claims in past 2 years, N (%), n=340\*                                                                                                    
    None                                                       110 (95.7)                             105 (92.9)                                                105 (93.8)
    1                                                          4 (3.5)                                8 (7.1)                                                   7 (6.3)
    ≥2                                                         1 (0.9)                                0 (0.0)                                                   0 (0.0)
   Chiropractic care in past 3 months, N (%), n=340            4 (3.5)                                8 (7.1)                                                   5 (4.5)
   Physical therapy in past 3 months, N (%), n=340\*           5 (4.3)                                3 (2.7)                                                   6 (5.4)
  Postinjury diagnosis and symptoms                                                                                                                             
   WAD grade: N (%)                                                                                                                                             
     I                                                         41 (35.7)                              34 (30.1)                                                 26 (23.2)
     II                                                        73 (64.3)                              79 (69.9)                                                 86 (76.8)
   Body part injured: N (%)                                                                                                                                     
     Neck                                                      115 (100.0)                            113 (100.0)                                               112 (100.0)
     Face                                                      12 (10.4)                              13 (11.5)                                                 13 (11.6)
     Low back                                                  73 (63.5)                              74 (65.2)                                                 74 (66.1)
     Arm(s)                                                    48 (41.7)                              47 (41.6)                                                 52 (46.4)
     Leg(s)                                                    31 (27.0)                              41 (36.3)                                                 38 (33.9)
     Foot/feet                                                 9 (7.8)                                14 (12.4)                                                 19 (17.0)
     Abdomen/chest/groin                                       33 (28.7)                              39 (34.5)                                                 43 (38.4)
     Shoulder(s)                                               92 (80.0)                              95 (84.1)                                                 92 (82.1)
     Mid-back                                                  88 (76.5)                              81 (71.7)                                                 78 (69.6)
     Head                                                      57 (49.6)                              53 (46.9)                                                 61 (54.5)
     Hand(s)                                                   29 (25.2)                              27 (23.9)                                                 35 (31.2)
   Average pain in past 24 hours†                                                                                                                               
     Neck: mean (SD)                                           5.6 (2.1)                              5.7 (2.0)                                                 5.9 (2.1)
     Shoulder: mean (SD)                                       4.7 (2.7)                              4.8 (2.8)                                                 5.0 (2.9)
     Low back: mean (SD)                                       4.1 (3.2)                              4.1 (3.4)                                                 4.3 (3.5)
     Headache: mean (SD)                                       3.7 (3.3)                              3.5 (3.3)                                                 4.1 (3.4)
     Arm: mean (SD)                                            1.9 (2.7)                              2.4 (2.9)                                                 2.4 (3.1)
     Mid-back: mean (SD)                                       4.2 (3.0)                              4.2 (3.0)                                                 4.3 (3.4)
     Hand: median (IQR)                                        0.0 (0.0)                              0.0 (1.0)                                                 0.0 (3.0)
     Face: median (IQR)                                        0.0 (0.0)                              0.0 (0.0)                                                 0.0 (0.0)
     Leg: median (IQR)                                         0.0 (2.0)                              0.0 (4.0)                                                 0.0 (3.0)
     Foot: median (IQR)                                        0.0 (0.0)                              0.0 (0.0)                                                 0.0 (0.0)
     Abdomen/chest/groin: median (IQR)                         0.0 (1.0)                              0.0 (2.0)                                                 0.0 (4.0)
   Loss of consciousness, N (%), n=326\*                       0 (0.0)                                1 (0.9)                                                   0 (0.0)
   Loss of memory, N (%), n=324\*                              8 (7.2)                                12 (11.4)                                                 10 (9.3)
   Disorientation/confusion postcollision, N (%), n=330\*      38 (34.6)                              44 (39.6)                                                 51 (46.8)
  Postinjury healthcare                                                                                                                                         
   Attended hospital or emergency care, N (%), n=340\*         30 (26.1)                              29 (25.7)                                                 35 (31.2)
   Received healthcare since collision, N (%), n=340           67 (58.3)                              61 (54.0)                                                 71 (63.4)
  Preinjury comorbidities\*                                                                                                                                     
   Number of comorbidities‡: N (%)                                                                                                                              
     None                                                      13 (11.3)                              8 (7.1)                                                   10 (8.9)
     1--2                                                      48 (41.7)                              47 (41.6)                                                 54 (48.2)
    \>3                                                        54 (47.0)                              58 (51.3)                                                 48 (42.9)
   Muscle, bone, joint problems: N (%), n=340\*                                                                                                                 
     Does not have the condition                               65 (56.5)                              63 (55.7)                                                 66 (58.9)
     Mild effect or not at all                                 42 (36.5)                              39 (34.5)                                                 37 (33.0)
     Moderate to severe effect                                 8 (7.0)                                11 (9.7)                                                  9 (8.0)
   Allergies: N (%), n=340                                                                                                                                      
     Does not have the condition                               57 (49.6)                              59 (52.2)                                                 64 (57.1)
     Mild effect or not at all                                 50 (43.5)                              48 (42.5)                                                 44 (39.3)
     Moderate to severe effect                                 8 (7.0)                                6 (5.3)                                                   4 (3.6)
   Breathing problems: N (%), n=340                                                                                                                             
     Does not have the condition                               81 (70.4)                              81 (71.7)                                                 86 (76.8)
     Mild effect or not at all                                 22 (19.1)                              25 (22.1)                                                 22 (19.6)
     Moderate to severe effect                                 12 (10.4)                              7 (6.1)                                                   4 (3.6)
   Hypertension: N (%), n=340                                                                                                                                   
     Does not have the condition                               105 (91.3)                             100 (88.5)                                                90 (80.4)
     Mild effect or not at all                                 10 (8.7)                               9 (8.0)                                                   20 (17.9)
     Moderate to severe effect                                 0 (0.0)                                4 (3.5)                                                   2 (1.8)
   Cardiovascular problems: N (%), n=340                                                                                                                        
     Does not have the condition                               100 (87.0)                             100 (88.5)                                                100 (89.3)
     Mild effect or not at all                                 13 (11.3)                              8 (7.1)                                                   10 (8.9)
     Moderate to severe effect                                 2 (1.7)                                5 (4.4)                                                   2 (1.7)
   Gastrointestinal problems: N (%), n=340                                                                                                                      
     Does not have the condition                               97 (84.3)                              94 (83.2)                                                 97 (86.6)
     Mild effect or not at all                                 11 (9.6)                               11 (9.7)                                                  9 (8.0)
     Moderate to severe effect                                 7 (6.1)                                8 (7.1)                                                   6 (5.4)
   Diabetes: N (%), n=340                                                                                                                                       
     Does not have the condition                               112 (97.4)                             110 (97.3)                                                107 (95.5)
     Mild effect or not at all                                 3 (2.6)                                2 (1.8)                                                   5 (4.5)
     Moderate to severe effect                                 0 (0.0)                                0 (0.0)                                                   0 (0.0)
   Kidney/genitourinary problems: N (%), n=340                                                                                                                  
     Does not have the condition                               98 (85.2)                              95 (84.1)                                                 100 (89.3)
     Mild effect or not at all                                 11 (9.6)                               11 (9.7)                                                  9 (8.0)
     Moderate to severe effect                                 6 (5.2)                                7 (6.2)                                                   3 (2.7)
   Headache: N (%), n=340                                                                                                                                       
     Does not have the condition                               56 (48.7)                              51 (45.1)                                                 68 (60.7)
     Mild effect or not at all                                 48 (41.7)                              49 (43.4)                                                 36 (32.1)
     Moderate to severe effect                                 11 (9.6)                               13 (11.5)                                                 8 (7.1)
   Mental/emotional problems: N (%), n=340                                                                                                                      
     Does not have the condition                               85 (73.9)                              86 (76.1)                                                 87 (77.7)
     Mild effect or not at all                                 21 (18.3)                              14 (12.4)                                                 13 (11.6)
     Moderate to severe effect                                 9 (7.8)                                13 (11.5)                                                 12 (10.7)
   Cancer: N (%), n=340                                                                                                                                         
     Does not have the condition                               110 (95.7)                             110 (97.3)                                                106 (94.6)
     Mild effect or not at all                                 3 (2.6)                                3 (2.7)                                                   5 (4.5)
     Moderate to severe effect                                 2 (1.7)                                0 (0.0)                                                   1 (0.9)
   Expectation of recovery, N (%), n=340                                                                                                                        
    Get better soon                                            69 (60.0)                              43 (38.1)                                                 53 (47.3)
    Get better slowly                                          25 (21.7)                              45 (39.8)                                                 31 (27.7)
    Never get better/do not know                               21 (18.3)                              25 (22.1)                                                 28 (25.0)
   Health transition statement, N (%), n=340                                                                                                                    
    Excellent/very good                                        11 (9.6)                               9 (8.0)                                                   10 (8.9)
    Good                                                       24 (20.9)                              18 (15.9)                                                 26 (23.2)
    Fair/poor                                                  80 (69.6)                              86 (76.1)                                                 76 (67.9)
  SF-36 scores                                                                                                                                                  
   Physical CS (SF-36), mean (SD)                              40.2 (9.0)                             38.2 (9.4)                                                36.8 (9.4)
   Mental CS (SF-36), mean (SD)                                45.9 (12.7)                            45.2 (14.6)                                               45.1 (13.1)
   CES-D, mean (SD)                                            13.9 (11.9)                            15.9 (13.6)                                               16.5 (12.2)
  Vanderbilt Pain Management Inventory scores                                                                                                                   
   Active coping, mean (SD)                                    15.7 (3.5)                             15.2 (3.2)                                                14.2 (4.3)
   Passive coping, mean (SD)                                   14.3 (3.9)                             15.2 (3.9)                                                15.1 (4.5)
  Whiplash disability                                                                                                                                           
   WDQ, mean (SD)                                              49.6 (28.6)                            57.8 (29.9)                                               57.1 (28.9)

\*Fisher's exact test was used when expected cell counts was less than five in 25% or more of the cells.

†Kruskal-Wallis test was conducted where median (ranges) were reported.

‡Comorbidities include allergies, arthritis, blood problems, breathing problems, cancer, diabetes, digestive disorders, genitourinary problems, heart/circulation problems and headaches.

CES-D, Centre for Epidemiological Studies-Depression Scale; CS, component score; SF-36, 36-item Short Form Survey; WAD, whiplash-associated disorders; WDQ, Whiplash Disability Questionnaire.

Healthcare services {#s4c}
-------------------

The mean number of visits during the first 3 weeks of care was 3.8 (SD 2.3) for the government-regulated guideline group and 2.7 (SD 1.9) for the preferred-provider rehabilitation group. Similarly, it was 2.8 visits (SD 2.4) for government-regulated guideline and 2.7 (SD 2.5) for the preferred-provider rehabilitation during the subsequent 3 weeks. The education and activation group had a mean of 1.5 visits to general practitioners (SD 0.8) during the first 6 weeks of care.

A total of 48 participants from the preferred-provider and education and activations groups were referred for multidisciplinary evaluation. Twenty-two of the 28 (24.8%) referred participants from the preferred-provider group attended their multidisciplinary evaluation. In the education and activation group, 20 participants (17.9%) were referred and 19 attended.

Compared with the government-regulated guideline group, a higher proportion of participants in the other two groups received treatment outside of the protocol (online [supplementary appendix 6](#SP1){ref-type="supplementary-material"}). Specifically, they used more massage therapy, physiotherapy and chiropractic. Some participants visited their own general practitioner within the first 6 weeks of care (27.5% for government-regulated guideline group, 43.8% for the preferred-provider group, 34.8% for education and activation group).

Follow-up {#s4d}
---------

Follow-up rates at 12 months were 80.9% for the government-regulated guideline group; 84.1% for the preferred-provider group and 71.4% for those receiving education and activation. The follow-up rate for the primary outcome was 74.1% at 6 weeks, 65.3% at 3 months, 61.8% at 6 months, 54.4% at 9 months and 78.8% at 1 year. Following the 9 month follow-up, we adapted our follow-up strategy to minimise selection bias due to increasing attrition. Trial coordinators called participants who could not be reached by the research assistant and invited to talk to the research assistant to complete the final interview. Overall, 91.1% of participants provided follow-up data and were included in the analysis ([figures 1 and 2](#F1 F2){ref-type="fig"}). Not providing follow-up data was associated with consulting a lawyer, direction of impact, expectation of recovery, self-reported cardiovascular problems, self-reported gastrointestinal problems and mental and emotional problems prior to the collision (online [supplementary appendix 7](#SP1){ref-type="supplementary-material"}).

Self-reported global recovery {#s4e}
-----------------------------

The median time to recovery was 59 days (95% CI 55 to 68) for the government-regulated group, 105 days (95% CI 61 to 126) for the preferred-provider rehabilitation group and 108 days (95% CI 93 to 206) for the education and activation group ([figure 3](#F3){ref-type="fig"}). The time to recovery between groups was not significant (Χ^2^=3.96; 2 df: p=0.138). Compared with the government-regulated group, rate of recovery was 13% slower in the preferred-provider rehabilitation group (adjusted HRR=0.87; 95% CI 0.64 to 1.18) and 28% slower in the education and activation group (adjusted HRR=0.72; 95% CI 0.53 to 1.00).

![Intention-to-treat analysis for time to self-reported global recovery (reporting 'completely recovered' or 'much improved'). GP, general practitioner.](bmjopen-2017-021283f03){#F3}

Proportionality assumptions of the model {#s4f}
----------------------------------------

Our analysis showed that the interaction between treatment groups and the log of time was not statistically significant (time×general practitioner group, p=0.08; time×preferred-provider group, p=0.25). However, on observing the shape of the Kaplan-Meier curves, two possible inflection times were identified: the first one at 60 days and the second one at 80 days. Therefore, we built two post hoc piecewise proportional hazards models. The first model (split at 60 days) did not yield any substantial improvement compared with the original Cox model (likelihood ratio statistic=3.74; 2 df: p=0.15). However, the second model (split at 80 days) showed substantial improvement compared with the original Cox model (likelihood ratio statistic=7.76; 2 df: p=0.02). Compared with the government-regulated guideline group, the general practitioner (delivering education and activation) and preferred-provider groups had slower rates of recovery during the first 80 days (HRR=0.51, 95% CI 0.34 to 0.77 and HRR=0.67, 95% CI 0.46 to 0.96, respectively), but not beyond that (HRR=1.26, 95% CI 0.74 to 2.16 and HRR=1.33, 95% CI 0.78 to 2.27, respectively).

Secondary outcomes {#s4g}
------------------

Neck pain intensity, whiplash-related disability, depressive symptomatology and health-related quality of life improved in all groups during follow-up ([table 2](#T2){ref-type="table"}), but there were no significant differences between groups (p\>0.05; [table 3](#T3){ref-type="table"}).

###### 

Within-group differences from baseline to follow-up for secondary outcomes\*

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Outcome                                                             Government-regulated guideline\   Preferred-provider insurance-based rehabilitation\   General practitioner education and activation\
                                                                      Mean difference (95% CI)          Mean difference (95% CI)                             Mean difference (95% CI)
  ------------------------------------------------------------------- --------------------------------- ---------------------------------------------------- ------------------------------------------------
  Neck pain intensity                                                                                                                                        

   6 weeks (n=85; 79; 72)†                                            2.7 (2.1 to 3.3)                  2.2 (1.6 to 2.8)                                     2.4 (1.7 to 3.0)

   3 months (n=76; 70; 64)†                                           3.5 (2.9 to 4.0)                  3.3 (2.7 to 3.9)                                     3.3 (2.6 to 3.9)

   6 months (n=62; 66; 63)†                                           3.4 (2.8 to 4.1)                  3.2 (2.5 to 3.8)                                     3.6 (3.0 to 4.3)

   9 months (n=60; 45; 49)†                                           3.7 (3.1 to 4.3)                  4.0 (3.4 to 4.5)                                     3.8 (3.1 to 4.4)

   12 months (n=86; 81; 70)†                                          3.6 (3.0 to 4.2)                  3.2 (2.6 to 3.8)                                     3.6 (2.9 to 4.2)

  Whiplash disability                                                                                                                                        

   6 weeks (n=80; 73; 68)†                                            17.7 (9.2 to 26.1)                19.9 (11.7 to 28.1)                                  20.9 (13.0 to 28.9)

   3 months (n=69; 62; 61)†                                           25.9 (18.2 to 33.6)               30.6 (22.9 to 38.3)                                  28.3 (20.9 to 35.7)

   6 months (n=57; 61; 56)†                                           22.3 (13.9 to 30.7)               29.9 (21.9 to 37.8)                                  35.6 (28.2 to 43.0)

   9 months (n=60; 37; 44)†                                           29.4 (21.8 to 36.9)               41.7 (34.8 to 48.6)                                  36.7 (29.8 to 43.6)

   12 months (n=50; 43; 37)†                                          29.3 (21.4 to 37.2)               39.8 (32.3 to 47.3)                                  37.0 (29.7 to 44.2)

  Depressive symptomatology                                                                                                                                  

   6 weeks (n=78; 71; 65)†                                            3.0 (−0.3 to 6.3)                 2.0 (−1.5 to 5.4)                                    4.8 (1.5 to 8.0)

   3 months (n=69; 61; 59)†                                           4.2 (0.8 to 7.6)                  6.8 (3.6 to 9.9)                                     5.7 (2.6 to 8.7)

   6 months (n=55; 59; 56)†                                           3.1 (−0.5 to 6.7)                 5.6 (2.1 to 9.0)                                     7.1 (4.0 to 10.2)

   9 months (n=58; 37; 43)†                                           5.3 (2.1 to 8.4)                  7.5 (4.3 to 10.8)                                    10.0 (7.4 to 12.6)

   12 months (n=49; 43; 36)†                                          6.0 (2.9 to 9.2)                  7.3 (4.1 to 10.5)                                    8.3 (5.3 to 11.3)

  Health-related quality of life (SF-36)---Physical Component Score                                                                                          

   6 weeks (n=80; 74; 69)†                                            −6.7 (−9.4 to −4.0)               −6.2 (−8.7 to −3.7)                                  −6.8 (−9.4 to −4.2)

   3 months (n=69; 62; 60)†                                           −7.8 (−10.2 to −5.4)              −8.1 (−10.6 to −5.7)                                 −8.6 (−11.2 to −6.0)

   6 months (n=57; 61; 58)†                                           −9.1 (−11.6 to −6.7)              −9.9 (−12.3 to −7.5)                                 −10.2 (−12.9 to −7.5)

   9 months (n=60; 61; 58)†                                           −7.5 (−10.0 to −5.0)              −12.0 (−14.5 to −5.0)                                −11.2 (−13.7 to −8.6)

   12 months (n=59; 52; 46)†                                          −9.9 (−12.2 to −7.6)              −11.0 (−13.4 to −8.6)                                −11.6 (−14.1 to −9.1)

  Health-related quality of life (SF-36)---Mental Component Score                                                                                            

   6 weeks (n=80; 74; 69)†                                            −3.3 (−6.8 to −0.1)               −2.1 (−5.7 to −1.5)                                  −1.5 (−4.9 to −1.9)

   3 months (n=69; 62; 60)†                                           −5.0 (−8.3 to −1.7)               −6.8 (−10.0 to −3.6)                                 −7.0 (−16.5 to −2.6)

   6 months (n=57; 61; 58)†                                           −2.6 (−6.2 to −1.1)               −5.6 (−9.1 to −2.2)                                  −5.8 (−15.7 to −4.1)

   9 months (n=60; 38; 45)†                                           −5.5 (−8.8 to −2.2)               −7.8 (−11.1 to −4.5)                                 −8.5 (−11.4 to −5.5)

   12 months (n=59; 52; 46)†                                          −7.1 (−10.3 to −3.9)              −7.4 (−10.6 to −4.1)                                 −7.3 (−10.5 to −4.1)
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Sample sizes for government-regulated guideline, preferred-provider insurance-based rehabilitation and general practitioner education and activation, respectively.

†Using generalised estimating equation models, there was statistically significant improvement over time in all groups (p\<0.0001). Clinically important differences were two points on Numeric Rating Scale, 21.4 points on Whiplash Disability Questionnaire, 7.7 points on the SF-36 Physical Component Score and 10% for Centre for Epidemiological Studies Depression and SF-36 Mental Component Score.

SF-36,  36-item Short Form Survey.

###### 

Between-group differences for secondary outcomes\*

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Outcome                                                             Government-regulated guideline group minus preferred-provider rehabilitation group\   Government-regulated guideline group minus general practitioner education and activation group\   Preferred-provider rehabilitation group minus general practitioner education and activation group\
                                                                      Mean difference (95% CI)                                                              Mean difference (95% CI)                                                                          Mean difference (95% CI)
  ------------------------------------------------------------------- ------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------
  Neck pain intensity                                                                                                                                                                                                                                         

   6 weeks                                                            0.5 (−0.3 to 1.3)                                                                     0.2 (−0.7 to 1.0)                                                                                 0.6 (−0.2 to 1.5)

   3 months                                                           0.5 (−0.3 to 1.4)                                                                     0.0 (−1.0 to 0.9)                                                                                 0.5 (−0.4 to 1.4)

   6 months                                                           0.2 (−0.7 to 1.2)                                                                     −0.1 (−1.1 to 0.9)                                                                                0.1 (−0.8 to 1.1)

   9 months                                                           0.2 (0.8 to 1.2)                                                                      0.2 (−0.9 to 1.2)                                                                                 0.4 (−0.6 to 1.4)

   12 months                                                          0.7 (−0.1 to 1.5)                                                                     −0.3 (−1.2 to 0.6)                                                                                0.4 (−0.5 to 1.2)

  Whiplash disability                                                                                                                                                                                                                                         

   6 weeks                                                            0.0 (−8.4 to 8.4)                                                                     0.2 (−9.2 to 9.5)                                                                                 0.2 (− 8.7 to 9.0)

   3 months                                                           3.0 (−6.2 to 12.2)                                                                    −1.1 (−10.9 to 8.7)                                                                               1.9 (−7.5 to 11.2)

   6 months                                                           −5.5 (−15.9 to 4.9)                                                                   −2.7 (−13.2 to 7.8)                                                                               −8.2 (−18.7 to 2.2)

   9 months                                                           −1.8 (−13.2 to 9.6)                                                                   2.8 (−8.7 to 14.3)                                                                                1.0 (−10.1 to 12.0)

   12 months                                                          −4.8 (−15.2 to 5.6)                                                                   3.3 (−7.3 to 14.0)                                                                                −1.5 (−12.3 to 9.3)

  Depressive symptomatology                                                                                                                                                                                                                                   

   6 weeks                                                            1.7 (−1.8 to 5.2)                                                                     −2.5 (−6.3 to 1.3)                                                                                −0.8 (−4.4 to 2.8)

   3 months                                                           −0.7 (−4.8 to 3.4)                                                                    −0.2 (−4.4 to 4.0)                                                                                −0.9 (−5.1 to 3.3)

   6 months                                                           −1.5 (−5.7 to 2.6)                                                                    −0.6 (−5.1 to 3.8)                                                                                −2.2 (−7.0 to 2.7)

   9 months                                                           0.6 (−3.8 to 5.0)                                                                     −2.8 (−7.6 to 2.0)                                                                                −2.2 (−6.6 to 2.2)

   12 months                                                          0.9 (−4.1 to 5.8)                                                                     −1.8 (−6.8 to 3.2)                                                                                −0.9 (−5.7 to 3.9)

  Health-related quality of life (SF-36)---Physical Component Score                                                                                                                                                                                           

   6 weeks                                                            0.4 (−2.8 to 3.7)                                                                     0.2 (−3.2 to 3.5)                                                                                 0.6 (−2.4 to 3.7)

   3 months                                                           0.4 (−3.0 to 3.9)                                                                     −0.2 (−3.9 to 3.5)                                                                                0.2 (−3.1 to 3.5)

   6 months                                                           0.4 (−3.0 to 3.8)                                                                     −1.0 (−5.0 to 2.9)                                                                                −0.7 (−4.4 to 3.1)

   9 months                                                           3.8 (−0.5 to 8.2)                                                                     −2.9 (−7.4 to 1.6)                                                                                0.9 (−3.1 to 4.9)

   12 months                                                          1.6 (−2.0 to 5.1)                                                                     −2.1 (−6.1 to 2.0)                                                                                −0.5 (−4.4 to 3.4)

  Health-related quality of life (SF-36)---Mental Component Score                                                                                                                                                                                             

   6 weeks                                                            −3.3 (−7.4 to 0.9)                                                                    −0.8 (−4.9 to 3.2)                                                                                −4.1 (−8.4 to 0.3)

   3 months                                                           −0.7 (−5.4 to 4.0)                                                                    −0.7 (−5.3 to 4.0)                                                                                −1.3 (−6.2 to 3.6)

   6 months                                                           2.2 (−2.7 to 7.1)                                                                     0.3 (−4.1 to 4.7)                                                                                 2.6 (−2.5 to 7.6)

   9 months                                                           −0.3 (−6.1 to 5.5)                                                                    1.8 (−3.6 to 7.2)                                                                                 1.5 (−4.1 to 7.1)

   12 months                                                          −1.5 (−6.7 to 3.8)                                                                    −0.6 (−5.2 to 4.0)                                                                                −2.1 (−7.2 to 3.0)
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Clinically important differences were two points on Numeric Rating Scale, 21.4 points on Whiplash Disability Questionnaire, 7.7 points on the SF-36 Physical Component Score and 10% for Centre for Epidemiological Studies Depression and SF-36 Mental Component Score.

SF-36, 36-item Short Form Survey.

The median time on insurance benefits was similar between groups: 300 days (95% CI 256 to 373) for the government-regulated guideline group; 283 days (95% CI 221 to 393) for preferred-provider rehabilitation and 321 days (95% CI 250 to 417) for the education and activation group (online [supplementary appendix 8](#SP1){ref-type="supplementary-material"}). Compared with the government-regulated guideline group, there were no differences in the rate of claim closure between groups (preferred-provider rehabilitation group: HRR=1.01, 95% CI 0.71 to 1.37; education and activation group: HRR=0.91, 95% CI 0.65 to 1.30).

Adverse events {#s4h}
--------------

There were no adverse events related to the study interventions. However, nine participants reported the following conditions during the trial: 1) government-regulated guideline group: suicidal ideation (n=1), otosclerosis (n=1), transient vertigo (n=1), one urinary retention and foot drop (n=1); 2) preferred-provider rehabilitation group: detached retina (n=1), arthroscopic knee surgery (n=1) and lump in neck (n=1) and 3) education and activation group: hip fracture (n=1) and ankle fracture (n=1).

Discussion {#s5}
==========

We conducted a pragmatic randomised controlled trial of the effectiveness of a government-regulated rehabilitation guideline for the management of acute WAD. We found that the government-regulated guideline was not associated with a statistically significant improvement in recovery compared with general practitioner education and activation or preferred-provider rehabilitation in patients with acute WAD grade I--II. Similarly, we did not find differences in secondary outcomes. However, our post hoc analysis suggests that the government-regulated rehabilitation guideline may have a short-term limited effect (first 80 days) on self-reported recovery. The reasons for this temporary effect are not known, but cannot be attributed to differential follow-up times. The median follow-up times (IQR) at the 6-week and 3-month follows-up were, respectively: 43 days (IQR 42--49) and 95 days (IQR 92--104) for the education and activation group; 44 days (IQR 41--51) and 96 days (IQR 91--107) for the preferred-provider group and 45 days (IQR 42--50) and 95 days (IQR 91--105) for the government-regulated guideline. While the role of chance cannot be ruled out, it is possible that additional care received by 41 participants in the preferred-provider and activation and education groups may have impacted perceived recovery. The median time for a multidisciplinary examination to occur was 55.5 days (IQR 47--70) for the preferred-provider group (n=22) and 55 days (IQR 35--85) days for the education and activation group (n=19). The median time to begin interdisciplinary rehabilitation was 64 days (IQR 57--782) and 65 days (IQR 49--157) from recruitment for the preferred provider and education and activation groups, respectively.

Our findings are partly consistent with the results of a previous randomised trial. Jull *et al* reported no differences in neck pain and disability (measured on Neck Disability Index) between participants allocated to multidisciplinary individualised treatments compared with usual care.[@R21] Similarly, we found no differences in secondary outcomes (including neck disability) between treatment arms. However, we found that government-regulated guideline may promote time-limited short-term faster self-perceived global recovery. Although these results may appear paradoxical, they are not contradictory; recovery for musculoskeletal injuries is not necessarily synonymous with resolution of symptoms; patients report recovery when they are able to adjust to their condition, or adapt to living with their condition.[@R70]

Our findings are significant because they suggest that guidelines developed and regulated by governments may improve self-perceived recovery from WAD. Although guidelines are developed to reduce the gap between research and clinical care, their use and adherence by clinicians is poor.[@R71] Our study suggests that the implementation of guidelines by government agencies could improve early recovery from traffic injuries.[@R73] This finding has implications beyond North America because WAD is associated with a high burden of disability throughout the world.[@R11]

Our trial provides important clinical information regarding the effective dose of care necessary to promote recovery in patients with acute WAD. Participants randomised to the government-regulated guideline received an average of 6.5 treatments during the first 6 weeks of care. This finding agrees with the results of a recent systematic review, which reported that effective multimodal interventions include an average of six visits during the first 8 weeks of care.[@R22] Future research examining potential dose-response relationships with treatment visits under a government-regulated guideline scheme and recovery is warranted.

We did not confirm the results from cohort studies which suggested that low-intensity general practitioner-directed care may be superior to other conservative management.[@R6] Several reasons may help explain this finding. First, previous results were from Saskatchewan in the mid-1990s when management of whiplash injuries was not guided by a treatment protocol, such as the government-regulated programme. A regulated management programme (especially when applied in a standardised manner from a randomised trial) may yield benefits over unguided usual care. Second, evidence-based knowledge translation strategies (since the mid-1990s in Canada) have mainly targeted rehabilitation practitioners (physiotherapists and chiropractors) rather than general practitioners.[@R29] This may have led to changes in the clinical management of WAD by the former groups of clinicians. Third, automobile insurance rehabilitation practices in Ontario may have created a culture where injured persons with WAD expect rehabiltation; one or two visits to a general practitioner may not be perceived as a form of rehabilitation. Patients may expect to receive rehabilitation care and may not perceive general practitioner-based activation and rehabilitation as sufficient. This may explain why more participants allocated to this group sought co-interventions. In contrast, the government-regulated guideline group did not receive multidisciplinary rehabilitation and sought fewer co-interventions outside of the study protocol. Finally, delivery of an educational intervention alone may be ineffective. Recent studies, as identified in a previous systematic review, reported that education interventions alone provide minimal or no benefit in the management of WAD.[@R15]

Study strengths and limitations {#s5a}
-------------------------------

Our study had several strengths. First, we recruited a consecutive sample of participants early after the injury from a single insurer (median 5--6 days). Second, variability in the delivery of multidisciplinary care was minimised because treatment was provided at the same clinics in a geographic location, but by independent clinicians. Third, our trial was informed by a pilot study. A summary of the results of the pilot study are provided in the associated protocol paper.[@R33] Finally, we used a valid and reliable patient-centred outcome that provides a global measure of recovery.

Our study had some limitations. First, it was not possible to blind participants to the received intervention. Second, a higher proportion of participants allocated to preferred-provider rehabilitation and to general practitioner education and activation care reported using healthcare services outside the study protocol. However, it is likely that a considerable proportion of these participants received government-regulated rehabilitation outside of the study because this was the standard of care at the time of the study, which would reduce the contrast between groups. Moreover, fewer co-interventions in the government-regulated guideline group adds further weight that the government-regulated rehabilitation was more effective. Third, the follow-up rate was 65.3% at 3 months, 61.8% at 6 months and 54.4% at 9 months for the primary outcome. However, the 12-month follow-up rate for the primary outcome was 78.8%. In addition, recovery was assessed at 3, 6, 9 and 12 months to calculate time to recovery, whereas participants may have recovered earlier during the interval periods. Moreover, those who consulted a lawyer about their claim at baseline or did not expect to get better/did not know about their recovery were more likely to drop out. However, we explored the confounding effect of expectation of recovery and consulting a lawyer, and these did not bias our analysis. Reasons reported for study withdrawal were: self-perceived lack of importance, dissatisfaction with care received and advised to withdraw by their lawyer. Finally, these results may not be generalisable to settings and other jurisdictions outside of Ontario.

Conclusion {#s6}
==========

The results of our trial suggest that a government-regulated guideline is not more effective than a physician-based education and activation or preferred-provider rehabilitation intervention in promoting global recovery of patients with acute WAD. Similarly, we found no differences in neck-specific outcomes, depression or quality of life between groups. However, the government-regulated guideline may be associated with temporary faster self-rated recovery in the first 80 days postinjury, but this finding needs to be validated in future research.
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